Docetaxel and Trametinib for KRAS-Mutant Recurrent NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Clin. Cancer Res 2023 May 26;[EPub Ahead of Print], SM Gadgeel, J Miao, JW Riess, J Moon, PC Mack, GJ Gerstner, TF Burns, A Taj, WL Akerley, KH Dragnev, N Laudi, MW Redman, JE Gray, DR Gandara, K KellyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.